DOLK Antibody

What is DOLK and why is it significant for research?

DOLK (Dolichol Kinase) is an endoplasmic reticulum resident enzyme that catalyzes CTP-mediated phosphorylation of dolichol, which is the terminal step in de novo dolichyl monophosphate (Dol-P) biosynthesis. Dol-P serves as a lipid carrier essential for the synthesis of N-linked and O-linked oligosaccharides and for GPI anchors . The enzyme contains a cytidine-5′-triphosphate (CTP) binding pocket in the C-terminal domain that faces the cytoplasmic side of the ER membrane. DOLK is also known by several alternate names including Transmembrane Protein 15 (TMEM15), KIAA1094, UNQ2422, and PRO4980 .

Research into DOLK is significant because mutations in this gene can cause autosomal recessive dilated cardiomyopathy and DOLK-CDG (Congenital Disorders of Glycosylation), highlighting its crucial role in normal cardiac and cellular function .

What types of DOLK antibodies are currently available for research applications?

Currently available DOLK antibodies for research include:

• Rabbit polyclonal antibodies against human DOLK (such as those from Atlas Antibodies)

• Epitope-specific antibodies targeting particular regions of DOLK, such as the 420-470 amino acid region

• Antibodies validated for specific applications including Western Blot (WB), Immunohistochemistry (IHC), and Immunocytochemistry/Immunofluorescence (ICC-IF)

Most commercially available DOLK antibodies are unconjugated, but can be used with appropriate secondary detection systems depending on the experimental application .

What is the expression pattern of DOLK across different tissues?

DOLK exhibits distinct tissue-specific expression patterns which may help explain the tissue-restricted clinical phenotypes observed in DOLK-related disorders. According to expression studies:

• Highest expression levels of DOLK mRNA are found in fetal and adult brain

• In fetal tissues, high expression is observed in skeletal muscle and heart

• In adult tissues, heart shows particularly high expression after brain

• DOLK is expressed in the endoplasmic reticulum membrane as a multi-pass membrane protein

This expression pattern correlates with the clinical manifestations seen in patients with DOLK mutations, including cardiomyopathy and neurological symptoms .

What are the optimal experimental conditions for using DOLK antibodies in Western blotting?

For Western blot applications with DOLK antibodies, researchers should consider the following protocol:

• Sample preparation:

  • Prepare protein lysates from tissues or cells using suitable lysis buffers containing protease inhibitors

  • For membrane proteins like DOLK, consider specialized extraction buffers

• Protein separation and transfer:

  • Separate 20-50 μg of protein by SDS-PAGE (10-12% gel recommended)

  • Transfer to PVDF or nitrocellulose membrane

• Antibody incubation:

  • Block membrane with 5% non-fat milk or BSA in TBST

  • Dilute primary DOLK antibody at 1:500-1:2000 ratio in blocking buffer

  • Incubate overnight at 4°C

  • Wash thoroughly and incubate with appropriate HRP-conjugated secondary antibody

• Detection and analysis:

  • Visualize using ECL reagent

  • Expected molecular weight should be verified against product specifications

For optimal results, researchers should empirically determine the ideal concentration for their specific experimental conditions, starting with the manufacturer's recommended dilution range .

How can researchers optimize immunohistochemistry protocols for DOLK antibodies?

When performing immunohistochemistry with DOLK antibodies, the following protocol optimizations should be considered:

• Tissue preparation:

  • Use freshly fixed tissue sections (4% paraformaldehyde recommended)

  • For paraffin-embedded sections, appropriate antigen retrieval is critical (typically heat-mediated citrate buffer pH 6.0)

• Protocol modifications for membrane proteins:

  • Consider permeabilization steps to improve antibody access to ER membrane proteins

  • Use detergents such as 0.1-0.3% Triton X-100 in blocking and antibody diluent buffers

• Staining controls:

  • Include positive controls (tissues known to express DOLK, such as heart or brain)

  • Use negative controls (secondary antibody only or DOLK-deficient tissues)

  • Consider parallel staining with antibodies against ER markers to confirm localization

• Signal detection:

  • For heart tissue sections, comparing alpha-dystroglycan, beta-dystroglycan, beta-sarcoglycan, and desmin staining patterns can provide valuable context for DOLK function

Researchers should adjust incubation times and antibody concentrations based on their specific tissue samples and detection systems.

How can Design of Experiment (DOE) approaches improve DOLK antibody assay development?

Design of Experiment (DOE) approaches can significantly enhance DOLK antibody assay development and optimization. Based on established DOE methods for antibody assays:

• Response Surface Methodology (RSM) DOE:

  • Systematically evaluates multiple factors simultaneously to identify optimal conditions

  • Example factors for optimization include:

    • Antibody concentration

    • Antigen concentration

    • Incubation time

    • Buffer composition

    • Secondary antibody concentration

• Central composite design implementation:

  • Reduces experimental runs while maintaining statistical power

  • Can be executed in blocks to manage workload (e.g., 8 runs instead of 16 runs at once)

• Factor evaluation and optimization:

  • For binding assays: optimize coating concentration, assay incubation time, and secondary antibody concentration

  • For cell-based assays: optimize cell density, assay incubation time, and substrate incubation time

A QbD (Quality by Design) approach using DOE studies allows for a thorough understanding of the method design space, which is beneficial when transferring assays to other laboratories and developing assays for future research applications .

How can DOLK antibodies be used to study the pathophysiology of DOLK-related dilated cardiomyopathy?

DOLK antibodies offer multiple approaches to investigate the pathophysiology of DOLK-related dilated cardiomyopathy:

• Comparative expression analysis:

  • Use immunohistochemistry and Western blotting to compare DOLK protein levels and localization in normal versus DCM heart tissues

  • Analyze DOLK expression in different cardiac cell types (cardiomyocytes, fibroblasts, endothelial cells)

• Glycosylation pathway analysis:

  • Investigate how DOLK mutations affect O-mannosylation of alpha-dystroglycan, a critical process in cardiac function

  • Use WGA-enriched and non-enriched heart homogenates for Western blotting of alpha-dystroglycan, beta-dystroglycan, and related proteins

• Functional assessment:

  • Employ laminin overlay assays to evaluate glycosylation-dependent laminin binding capacity, which is compromised in DOLK-deficient tissues

  • Analyze the impact of DOLK mutations on protein interactions within the dystroglycan complex

• Mutation-specific effects:

  • Compare different DOLK mutations to understand correlations between specific mutations and clinical phenotypes

  • Employ yeast complementation assays using the DOLK ortholog (SEC59) to assess the functional consequences of different mutations, as demonstrated in previous research

This approach revealed that certain DOLK mutations show milder underglycosylation patterns compared to others, which correlates with the clinical severity spectrum .

What experimental approaches can verify the specificity of DOLK antibodies?

Verifying antibody specificity is crucial for reliable research. For DOLK antibodies, the following approaches are recommended:

• Genetic validation:

  • Compare antibody signal in wild-type versus DOLK-knockout or knockdown systems

  • Analyze signal in cells expressing different levels of DOLK protein

• Epitope mapping and competition:

  • Perform peptide competition assays using the immunizing peptide (e.g., the 420-470 aa region for specific antibodies)

  • Compare antibodies targeting different epitopes of DOLK

• Recombinant protein controls:

  • Use purified recombinant DOLK protein as a positive control

  • Express tagged versions of DOLK and compare detection with tag-specific and DOLK-specific antibodies

• Cross-species reactivity:

  • Validate specificity across species (e.g., human and mouse) where the antibody claims cross-reactivity

  • Compare expression patterns to known tissue distribution of DOLK

• Functional correlation:

  • Correlate antibody signal with functional assays measuring DOLK enzymatic activity

  • Confirm that signal intensity correlates with expected protein levels in different experimental conditions

Each validation approach should include appropriate positive and negative controls to ensure reliable interpretation of results.

How can researchers use DOLK antibodies to investigate protein-protein interactions in the glycosylation pathway?

DOLK antibodies can be valuable tools for uncovering protein-protein interactions within the glycosylation pathway:

• Co-immunoprecipitation approaches:

  • Use DOLK antibodies to pull down native protein complexes

  • Identify interacting partners by mass spectrometry or Western blotting

  • Important: Optimize extraction conditions to maintain membrane protein interactions

• Proximity labeling techniques:

  • Generate DOLK fusion proteins with BioID or APEX2 enzymatic tags

  • Identify proteins in close proximity to DOLK within the ER membrane

  • Validate potential interactions using co-immunoprecipitation with DOLK antibodies

• Fluorescence microscopy:

  • Perform dual immunostaining with DOLK antibodies and antibodies against potential interacting partners

  • Use super-resolution microscopy techniques to visualize co-localization at the subcellular level

  • Combine with FRET techniques for direct interaction studies

• In vitro binding assays:

  • Use purified DOLK (or domains thereof) to identify direct binding partners

  • Confirm interactions in cellular contexts using DOLK antibodies

These approaches can help elucidate DOLK's interactions with other enzymes in the dolichol phosphate pathway and with components of the N-glycosylation and O-mannosylation machinery.

How do DOLK deficiencies affect alpha-dystroglycan O-mannosylation and how can this be experimentally detected?

DOLK deficiencies can lead to abnormal alpha-dystroglycan O-mannosylation, which contributes to the pathophysiology of dilated cardiomyopathy. This can be experimentally detected through:

• Laminin overlay assay:

  • A specialized technique that assesses the functional glycosylation of alpha-dystroglycan

  • WGA-enriched heart homogenates are analyzed for their ability to bind laminin, which depends on proper O-mannosylation

  • Reduced laminin binding indicates defective glycosylation

• Glycosylation-specific antibody detection:

  • Use antibodies that recognize specific glycan structures on alpha-dystroglycan

  • Compare immunostaining patterns between normal and DOLK-deficient tissues

  • Analyze shifts in electrophoretic mobility due to altered glycosylation

• Combined analysis of dystroglycan complex components:

  • Perform Western blotting for alpha-dystroglycan, beta-dystroglycan, and beta-sarcoglycan

  • Analyze both WGA-enriched and non-enriched samples to distinguish glycosylation defects

  • Include desmin as a control for loading and tissue integrity

• Comparative tissue analysis:

  • Compare glycosylation patterns across multiple tissues to understand tissue-specific effects

  • Correlate with DOLK expression levels in different tissues

These methods have successfully demonstrated that nonsyndromic dilated cardiomyopathy can result from DOLK-CDG via deficient O-mannosylation of alpha-dystroglycan .

What are the considerations for using DOLK antibodies in functional rescue experiments?

When designing functional rescue experiments using DOLK antibodies to monitor protein expression, researchers should consider:

• Expression system selection:

  • Choose appropriate cell types that either naturally express DOLK or can support its proper folding and localization

  • Consider using cardiac cell lines for studies related to cardiomyopathy

• Construct design for rescue experiments:

  • Design wild-type and mutant DOLK expression constructs

  • Include epitope tags that don't interfere with the antibody binding region

  • Ensure proper targeting to the ER membrane

• Experimental validation approach:

  • Use DOLK antibodies to confirm expression levels of rescue constructs

  • Employ yeast complementation assays with SEC59 (yeast DOLK ortholog) to validate functional rescue

  • Monitor glycosylation of reporter proteins like CPY in yeast or alpha-dystroglycan in mammalian cells

• Quantitative assessment:

  • Establish dose-response relationships between DOLK expression and functional outcomes

  • Use Western blotting with DOLK antibodies to quantify expression levels

• Controls and characterization:

  • Include appropriate controls (empty vector, inactive mutants)

  • Characterize subcellular localization using immunofluorescence with DOLK antibodies

  • Verify enzymatic activity through functional assays

Previous studies successfully used this approach to demonstrate that different DOLK mutations have varying effects on glycosylation, with some mutants showing partial functional rescue compared to others .

What are common technical challenges when working with DOLK antibodies and how can they be addressed?

Researchers working with DOLK antibodies may encounter several challenges that can be addressed through specific technical approaches:

• Membrane protein extraction issues:

  • Challenge: Insufficient solubilization of DOLK from ER membranes

  • Solution: Use specialized extraction buffers containing appropriate detergents (e.g., 1% Triton X-100, 0.5% sodium deoxycholate, or 0.1% SDS)

  • Approach: Try different detergent combinations and optimize extraction time and temperature

• Specificity concerns:

  • Challenge: Cross-reactivity with other kinases or membrane proteins

  • Solution: Validate using knockout/knockdown controls and peptide competition assays

  • Approach: Compare results from multiple antibodies targeting different epitopes when possible

• Signal intensity problems:

  • Challenge: Weak signal due to low abundance of DOLK

  • Solution: Enhance detection using signal amplification methods or concentrate samples

  • Approach: For Western blotting, consider longer exposure times and more sensitive detection reagents

• Tissue-specific optimization:

  • Challenge: Different fixation requirements for various tissues

  • Solution: Optimize fixation and antigen retrieval protocols for each tissue type

  • Approach: Compare different fixatives and antigen retrieval methods (heat-induced vs. enzymatic)

• Background reduction:

  • Challenge: High background in immunohistochemistry or Western blotting

  • Solution: Optimize blocking conditions and increase washing stringency

  • Approach: Test different blocking agents (milk, BSA, normal serum) and include longer/additional washing steps

Each of these challenges requires systematic troubleshooting and may need adaptation based on the specific experimental system and antibody being used.

How can researchers integrate DOLK antibody data with other experimental approaches for comprehensive glycosylation pathway analysis?

Integrating DOLK antibody data with complementary experimental approaches provides a more comprehensive understanding of glycosylation pathways:

• Multi-omics integration strategy:

  • Combine DOLK antibody-based protein expression data with transcriptomics (RNA-seq)

  • Integrate with glycomics data to correlate DOLK levels with global glycosylation patterns

  • Include metabolomics data focusing on dolichol and dolichol phosphate levels

• Functional genomics coordination:

  • Correlate DOLK antibody staining with CRISPR/Cas9 screening results for glycosylation pathway components

  • Use genetic manipulation of DOLK (knockdown, knockout, overexpression) alongside antibody detection

• Enzymatic activity correlation:

  • Develop assays to measure DOLK enzymatic activity in vitro and in cell lysates

  • Correlate enzyme activity with protein expression levels detected by antibodies

  • Compare wild-type and mutant DOLK protein levels with their respective activities

• Model system translation:

  • Apply findings from yeast SEC59 complementation assays to mammalian systems

  • Use DOLK antibodies to confirm expression levels in both systems

  • As demonstrated in previous research, yeast models can effectively evaluate the functional impact of DOLK mutations identified in patients

• Clinical correlation:

  • Analyze DOLK expression in patient samples using antibodies

  • Correlate with clinical parameters and glycosylation biomarkers

  • Connect specific mutations with expression levels and glycosylation defects

This integrated approach allows researchers to establish causative relationships between DOLK deficiencies, glycosylation abnormalities, and clinical phenotypes.